

## Essilor

Price EUR111.80

Solid LFL growths in 2015 and 2016 at the (slight) expense of profitability

Fair Value EUR134 (+20%)

BUY-Top Picks

Bloomberg	EF FP
Reuters	ESSI.PA
12-month High / Low (EUR)	123.6 / 99.3
Market Cap (EUR)	24,200
Ev (BG Estimates) (EUR)	25,798
Avg. 6m daily volume (000)	578.4
3y EPS CAGR	14.2%

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.1%	-8.0%	-2.0%	-2.8%
Consumer Gds	2.6%	-8.5%	-5.4%	-6.2%
DJ Stoxx 600	0.1%	-13.3%	-15.3%	-10.1%

YEnd Dec. (€m)	2014	2015e	2016e	2017e
Sales	5,670	6,730	7,199	7,700
% change		18.7%	7.0%	7.0%
EBITDA	1,043	1,275	1,382	1,501
EBIT	1,222	1,215	1,322	1,436
% change		-0.6%	8.8%	8.6%
Net income	929.3	775.3	865.6	963.3
% change		-16.6%	11.7%	11.3%

	2014	2015e	2016e	2017e
Operating margin	21.6	18.1	18.4	18.7
Net margin	16.4	11.5	12.0	12.5
ROE	18.9	14.5	14.3	14.6
ROCE	16.9	21.2	21.8	22.4
Gearing	34.6	28.0	18.5	12.5

(€)	2014	2015e	2016e	2017e
EPS	3.05	3.66	4.08	4.54
% change	-	19.9%	11.7%	11.3%
P/E	36.7x	30.6x	27.4x	24.6x
FCF yield (%)	3.3%	2.8%	3.8%	4.3%
Dividends (€)	1.05	1.15	2.15	3.15
Div yield (%)	0.9%	1.0%	1.9%	2.8%
EV/Sales	4.6x	3.8x	3.5x	3.3x
EV/EBITDA	24.9x	20.2x	18.4x	16.7x
EV/EBIT	21.3x	21.2x	19.2x	17.5x



FY15 sales increased 18.4% as reported and 4.6% LFL to EUR6,716m, in line with expectations (EUR6,724m and +4.6% LFL) and the company's guidance ("at least +4.5% LFL"). In Q4 alone, sales grew at the same pace than in Q3 (+4.8% LFL vs. +4.4% in 9M). The FY contribution margin expanded 20bp to 18.8% consistent with the FY target ("at least 18.8%") but a bit shy of CS at 18.9%. This "cautiousness" is also reflected in the margin guidance for 2016 ("at least 18.8%" vs. CS: 19.3%), is it because of further marketing expenses or due to a higher dilutive impact from M&A? The sales guidance is reassuring ("around +5% LFL", "exceed 8% FX-n" vs. CS: +5.1%e / BG: +5%e). Analysts' meeting today at 10am (Paris time).

## ANALYSIS

- FY15 sales of EUR6,716m up 18.4% as reported and 4.6% LFL.** Acquisitions contributed 3.9pp, implying a higher scope effect in Q4 (+3.2%) than in Q3 (+1.7%) thanks to the numerous partnerships signed around the end of the year. As such, the FX-n growth amounted to 8.5% over 2015, in line with the company's guidance of "8-11% growth". It is worth noting the LFL growth acceleration in H2 with +5% vs. +4.2% in H1.
- Still a strong end to the year in Europe and the US.** Besides healthier market trends in those two regions, Essilor also benefited from its successful combination of innovation (*Crizal Prevencia*, *Eyezen*, etc.) and media campaigns: growth in **Europe** was 4.5% (Q3: +4% / 9M: +3.8%), whilst the group achieved 4.8% growth in **North America** (Q3: +4.4% / 9M: +4.2%), also helped by the focus on key accounts (EyeMed, Wal-Mart, etc.).
- Good trends in AMEA but slowdown in LatAm.** Sales in **AMEA** increased by 7.6%, representing a slight acceleration vs. Q3 and 9M trends (+5.9% and +5.6% respectively) fuelled by good trends in India (DD growth) and in China (HSD increase). The performance in **LatAm** has softened in Q4 (+4.7% vs. 7.4% in Q3 and +9.2% in 9M) given: (i) a demanding comparison base (Q4 14: +13.7%) and (ii) a volatile environment, particularly in Brazil which has already slowed down in Q3 (low single-digit growth vs. +9% in H1), partly offset by faster gains in Mexico and Colombia.
- Dynamic Readers & Sun (+10.2%).** This momentum is driven by the ramp up in the CVS contract (7,800+ stores) and by robust growths achieved by the sunglass band portfolio. Last but not least, sales in **Equipment** remained in the negative territory (-13.6%) due to intra-group restatements and a volatile environment in emerging markets (Rx labs have decreased their capex investments).

## Essilor LFL quarterly sales:

% change	Q1 15	Q2 15	Q3 15	Q4 15	2015
North America	4.5	3.7	4.4	4.8	4.4
Europe	2.5	5.0	4.0	4.5	4.0
Asia-Pacific-Middle-East- Africa	5.6	5.2	5.9	7.6	6.1
Latin America	10.0	10.5	7.4	4.7	8.0
<b>Lenses &amp; Optical Instruments</b>	<b>4.4</b>	<b>4.9</b>	<b>4.8</b>	<b>5.2</b>	<b>4.8</b>
Equipment	-2.1	-7.1	-6.4	-13.6	-8.1
Readers & Sun	1.8	3.2	9.9	15.3	7.3
<b>Total group</b>	<b>4.0</b>	<b>4.4</b>	<b>4.8</b>	<b>5.3</b>	<b>4.6</b>

Source: Company Data

- The FY15 contribution margin (18.8%, +20bp) met the guidance ("at least 18.8%") but...** it came is slightly below the market expectations (BG and CS: 18.9%e). In our view the deviation might come from a more significant dilutive impact from bolt-on acquisitions in H2 as the group closed numerous deals in Q4. The **GM** expanded 100bp to 59.7% which enjoyed several tailwinds (product and price mix, synergies from the integration of TOI). The 22% increase in **S&D** costs reflects the strong acceleration in consumer marketing spend (EUR215m expected vs. EUR150m in 2014).
- Group net income rose 17.9% to EUR757m (CS: 767.5m).** The net income was affected by: (i) restructuring provisions of EUR22m (Rx labs in Europe), (ii) a less favourable financial result (-EUR63m vs. -EUR44m in 2014) as the net debt increased to EUR2.1bn vs. EUR1.8bn in 2014), and (iii) a higher tax rate (27.5% vs. 26% last year). As a reminder COO Laurent Vacherot expected the tax rate to decrease gradually by ~1 p.p. per year to come back to the "normative level" of ~26% by 2017.

(To be continued next page)

### Essilor 2015 adjusted results:

EURm	2014	2015	% change
Sales	5,670	6,716	18.4
Gross Profit	3,328	4,012	20.6
Gross Margin (%)	58.7	59.7	+100bp
Contribution from operations	1,057	1,263	19.4
As a % of sales	18.6	18.8	+20bp
Operating Profit	989	1,183	19.6
Net profit attributable to shareholders	642	757	17.9
EPS	3.05	3.57	17.0

Source: Company Data

- **FY16 outlook: reassuring sales guidance...** Essilor expects a sales growth of “around 5% LFL”, which is aligned with expectations (BG: +5%e / CS: +5.1%e). The top line increase is anticipated to “exceed 8% FX-n”, implying a higher contribution from acquisitions since we were expecting +7% FX-n. T
- **but is the contribution margin target too cautious?** Semantics is key: Essilor guides on a CM of “at least 18.8%”, which leaves room for a margin expansion this year. Yet, this guidance remains shy of our expectations (+30pb to 19.2% / CS: 19.3%). In our view this cautiousness might be explained by two major factors: (i) a more significant dilutive impact from bolt-on acquisitions since Essilor seems to expect a ~3pp impact from external growth in 2016 and (ii) another ramp-up in marketing expenses.

### VALUATION

- The share price might come under pressure pending further clarifications from the management about this cautious margin guidance. **However this possible negative market reaction must be put into perspective: (i) ceteris paribus a CM of 18.9% instead of 19.2% (our assumption) should only lead to 1.6% downward revision to our FY16 CM forecast and (ii) the profitability improvement has never been a key priority for the group (e.g.: CM remained almost stable over 2010-13) which prefers to fuel a solid top line growth.**
- Consequently we would recommend to take advantage of any weakness in the share price given the group’s sound fundamentals and a rather upbeat LFL growth outlook which is one of Essilor’s key performance indicators.

### NEXT CATALYSTS

- Analysts’ meeting today at 10am (Paris time) // Q1 15 Sales on 21<sup>st</sup> April 2016.

[Click here to download document](#)



**Analyst:**  
Cédric Rossi  
33(0) 1 70 36 57 25  
crossi@bryangarnier.com

**Consumer Analyst Team:**  
Nikolaas Faes  
Loïc Morvan  
Antoine Parison  
Virginie Roumage

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 63,4%

NEUTRAL ratings 28,4%

SELL ratings 8,2%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Geneva</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudentiel et de		FINMA	
(FCA)	resolution (ACPR)			

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..